Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2023—Agilent Technologies announced a partnership with Akoya Biosciences to develop chromogenic and immunofluorescent multiplex assays that include spatial analysis for biopharma companies developing precision cancer therapeutics. The agreement aims to deliver an end-to-end multiplex solution integrating Agilent’s Dako Omnis staining instrument and Akoya’s PhenoImager HT imaging platform.
February 2023—SD Biosensor and SJL Partners LLC, both based in South Korea, have completed the transaction to acquire Meridian Bioscience. Meridian will continue to operate as an independent entity, under new ownership, headquartered in Cincinnati. Meridian offers immunoassay and molecular raw materials for human and veterinarian diagnostics testing, and it plans to add service capabilities for lyophilized bead and lateral flow test manufacturing.
February 2023—Thermo Fisher Scientific announced the FDA has granted emergency use authorization for its Applied Biosystems TaqPath Monkeypox/Orthopox Virus DNA kit, a polymerase chain reaction test designed to detect non-variola orthopoxviruses, including monkeypox virus, in approximately three-and-a-half hours. The test is intended for the qualitative detection of DNA from monkeypox virus (clades one and two) and screening for non-variola orthopoxviruses in human lesion swab specimens from patients suspected of monkeypox infection by their health care provider. The test is for in vitro diagnostic use.
February 2023—Agilent Technologies announced an agreement with Quest Diagnostics that will enable providers and patients in the United States to access the Agilent Resolution ctDx First liquid biopsy next-generation sequencing test.
January 2023—Verichem Laboratories offers liquid-stable, ready-to-use clinical reference materials intended for calibration and calibration verification procedures for total cholesterol and high- and low-density lipoprotein assays.
January 2023—DiaSorin announced it has received FDA 510(k) clearance for its Simplexa Congenital CMV Direct kit. The molecular diagnostic test enables direct detection of cytomegalovirus DNA in saliva swab and urine specimens from babies 21 days old or younger. It is the first kit to receive FDA clearance for CMV detection from both saliva swab and urine specimens.
January 2023—ZeptoMetrix launched its NATtrol MS2 bacteriophage quantitative stock, intended for use as an internal process control for rt-PCR assays.
January 2023—HemoSonics has received FDA 510(k) clearance for the Quantra hemostasis system with QStat cartridge. The clearance of the QStat cartridge expands the Quantra system’s indications for use to include trauma and liver transplant procedures.
December 2022—Hologic has been awarded a $19 million contract from the Biomedical Advanced Research and Development Authority. The funding will help bring Hologic’s Panther Fusion SARS-CoV-2/Flu A/B/RSV and Aptima SARS-CoV-2 assays in line with the FDA’s in vitro diagnostic standards and support clinical efforts to obtain claims for nasal samples using the Panther Fusion as well as market authorization for COVID-19 testing of asymptomatic individuals who have reason to be tested. The Aptima SARS-CoV-2 assay received EUA in May 2020, and the CE-marked Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is under development in the United States. The project has been funded with federal funds from the U.S. Department of Health and Human Services, the Administration for Strategic Preparedness and Response, and BARDA.
December 2022—The FDA has cleared Nova Biomedical’s Nova Primary blood glucose reference analyzer. Nova Primary is designed to replace the YSI Stat Plus 2300 Glucose and L-Lactate analyzer, which has been discontinued by YSI.
